INS and Alzheimer disease: Although the mechanisms that precede and trigger brain damage during the silent pre-clinical period are not well understood, HFD-induced systemic metabolic alterations, including dysregulation of glucose and insulin metabolism, have emerged as promising factors driving pre-clinical AD.